Diagnostic and Treatment Approach for B Symptoms in Lymphoma

Diagnostic Workup

The European Society for Medical Oncology recommends HIV, hepatitis B, and hepatitis C screening for patients with suspected lymphoma and B symptoms 1
PET/CT scan is the gold standard for staging and should be performed in all patients with suspected lymphoma and B symptoms, as recommended by the European Society for Medical Oncology 1
MRI is recommended for suspected CNS involvement, as suggested by the European Society for Medical Oncology 1

Excisional lymph node biopsy is mandatory for reliable diagnosis, and fine needle aspiration alone is insufficient, according to the European Society for Medical Oncology 2, 1
Core needle biopsy is acceptable only when surgical biopsy is impractical or poses excessive risk, as stated by the European Society for Medical Oncology 1
Histology must follow WHO classification with immunophenotyping, as recommended by the European Society for Medical Oncology 2, 1

B symptoms alone mandate treatment initiation in follicular lymphoma, even without other high tumor burden criteria, as recommended by the European Society for Medical Oncology 2, 3
First-line therapy for follicular lymphoma includes obinutuzumab or rituximab combined with CHOP or bendamustine for 6 cycles, as suggested by the European Society for Medical Oncology 3
Immediate treatment is required regardless of stage when B symptoms are present in diffuse large B-cell lymphoma, according to the European Society for Medical Oncology 1
Standard therapy for diffuse large B-cell lymphoma includes R-CHOP every 21 days for 6-8 cycles, as recommended by the European Society for Medical Oncology 1

Extended anti-infectious prophylaxis should be considered after bendamustine-containing regimens, as suggested by the European Society for Medical Oncology 3
Prophylactic antiviral medication up to 2 years beyond last rituximab exposure is mandatory for hepatitis B positive patients, according to the European Society for Medical Oncology 3
Precautions to prevent tumor lysis syndrome are essential before initiating chemotherapy in patients with high tumor burden and B symptoms, as recommended by the European Society for Medical Oncology 1

Mid-treatment assessment after 3-4 cycles is necessary to evaluate symptom resolution and radiographic response, as suggested by the European Society for Medical Oncology 2, 1
PET/CT is recommended for end-of-treatment response evaluation using Deauville criteria, according to the European Society for Medical Oncology 1, 3
Persistent PET positivity after induction identifies patients with adverse prognosis, as stated by the European Society for Medical Oncology 3

B symptoms in lymphoma are defined as unexplained fever >38°C, drenching night sweats that require changing clothes or bedding, and unexplained weight loss >10% of body weight within 6 months, according to the Annals of Oncology 4, 5, 6
The American Society of Clinical Oncology recommends that B symptoms be considered in the staging and prognosis of lymphoma patients 4

B symptoms indicate systemic involvement and are important for staging and prognosis, with the presence of B symptoms denoted by adding the letter "B" to the stage (e.g., Stage IIB), while absence is denoted by "A" (e.g., Stage IIA) 5, 7
The European Society for Medical Oncology states that B symptoms often correlate with more advanced disease and may indicate the need for treatment initiation 4
In follicular lymphoma, therapy should be initiated upon development of B symptoms, as they indicate active disease requiring intervention, according to the National Comprehensive Cancer Network 4

B symptoms are included among the high tumor burden criteria in follicular lymphoma, along with bulky disease (>7 cm) or 3 lymph nodes in distinct areas >3 cm, symptomatic splenic enlargement, organ compression, pleural or peritoneal effusion, elevated LDH or β2-microglobulin, and cytopenias (neutrophils <1×10⁹/L, platelets <100×10⁹/L), as defined by the Annals of Oncology 4
The International Lymphoma Society recommends that these criteria be considered in the management of follicular lymphoma patients 4

Diagnostic workup should include thorough documentation of B symptoms as they impact staging and treatment decisions, according to the European Society for Medical Oncology 7, 8
B symptoms are important criteria for treatment initiation in follicular lymphoma, even in the absence of other high tumor burden criteria, as stated by the National Comprehensive Cancer Network 4

Pruritus, fatigue, and malaise are not considered B symptoms, despite being common in lymphoma patients, according to the Journal of Clinical Oncology 9

In Hodgkin lymphoma, B symptoms are incorporated into the Ann Arbor staging system, influencing treatment decisions, as stated by the Journal of Clinical Oncology 9
B symptoms serve as critical indicators for treatment initiation and prognostic stratification in non-Hodgkin lymphoma, as reported by the Journal of Clinical Oncology and Annals of Oncology 9, 10

The presence of B symptoms mandates immediate treatment initiation in follicular lymphoma, even in asymptomatic patients with advanced disease, according to Annals of Oncology 10
B symptoms are one of the key criteria that override the watch-and-wait approach in follicular lymphoma, as stated by Annals of Oncology 10